Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Gross Profit: 2023-2025

Historic Gross Profit for Immunome (IMNM) over the last 2 years, with Jun 2025 value amounting to $4.0 million.

  • Immunome's Gross Profit rose 69.84% to $4.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $12.6 million, marking a year-over-year increase of 16.74%. This contributed to the annual value of $9.0 million for FY2024, which is 35.50% down from last year.
  • Immunome's Gross Profit amounted to $4.0 million in Q2 2025, which was up 37.22% from $2.9 million recorded in Q1 2025.
  • In the past 5 years, Immunome's Gross Profit ranged from a high of $4.3 million in Q2 2023 and a low of $1.0 million during Q1 2024.
  • For the 3-year period, Immunome's Gross Profit averaged around $3.0 million, with its median value being $2.9 million (2024).
  • Per our database at Business Quant, Immunome's Gross Profit slumped by 56.47% in 2024 and then soared by 184.35% in 2025.
  • Immunome's Gross Profit (Quarterly) stood at $3.8 million in 2023, then decreased by 28.44% to $2.7 million in 2024, then skyrocketed by 69.84% to $4.0 million in 2025.
  • Its Gross Profit was $4.0 million in Q2 2025, compared to $2.9 million in Q1 2025 and $2.7 million in Q4 2024.